The National Academies Press

Currently Skimming:

Appendix A: Public Meeting Agendas and Submissions to the Committee
Pages 419-426

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.

From page 419... ... Department of Health and Human Services 2:30–2:50 Epidemiology of Sickle Cell Disease in the United States Mary Hulihan, Dr.P.H., Health Scientist, Epidemiology and Surveillance Branch, Division of Blood Disorders, Centers for Disease Control and Prevention 419 Read the entire page →
From page 420... ... Taylor VI, D isease, Howard University 3:30–4:00 of Advocacy in Improving the Patient Experience The Role and Outcomes Shirley Miller, M.A., Patient Advocate, Atrium Health Lakiea Bailey, Ph.D., Executive Director, Sickle Cell Community Consortium 4:00–4:30 Public Comments SECOND PUBLIC MEETING April 16, 2019 Keck Center of the National Academies 500 Fifth Street, NW Washington, DC 20001 Open Session 9:30 a.m. Welcome and Opening Remarks Marie Clare McCormick, M.D., Sc.D., Committee Chair 9:45 Impact of Sickle Cell Disease on Patients, Panel 1: The Families, and Communities Facilitator: Charmaine Royal, Ph.D., M.S., Committee Member 9:45–9:50 Panel Introductions 9:50–10:00 Robertson, M.B.A., J.D., Patient Advocate; Derek Co-Founder, Maryland Sickle Cell Disease Association 10:00–10:10 Adrienne Bell-Cors Shapiro, Co-Founder and Science Administrator, Axis Advocacy Read the entire page →
From page 421... ... Department of Education 11:25–11:35 P Weishaupt, J.D., Senior Attorney, Health Richard and Human Services, Community Legal Services of Philadelphia 11:35–11:45 Whitten-Shurney, M.D., Chief Executive Wanda Officer and Medical Director, Sickle Cell Disease Association of America, Michigan Chapter, Inc. Read the entire page →
From page 422... ... 422 ADDRESSING SICKLE CELL DISEASE 12:50–1:00 Speller-Brown, D.N.P., P.N.P.-B.C., Director, Barbara SCD Transition Clinic; Lead Sickle Cell Translational Research APN, Children's National Health System 1:00–1:10 Jeffrey Glassberg, M.D., Associate Professor, Emergency Medicine; Hematology and Medical Oncology, Mount Sinai 1:10–1:20 Jonassaint, Ph.D., Assistant Professor of Charles Medicine, Social Work and Clinical and Translational Science, Department of Medicine, University of Pittsburgh 1:20–1:40 Discussion 1:40 Break 1:55 Panel 4: Curative Therapies for Sickle Cell Disease Lakdawalla, Ph.D., Committee Facilitator: Darius Member 1:55–2:00 Panel Introductions 2:00–2:10 Betsy Myers, Ph.D., Program Director for Medical Research, Doris Duke Charitable Foundation 2:10–2:20 Mark Walters, M.D., Program Director, Alpha Stem Cell Clinic; Medical Director, Jordan Family Center for Bone Marrow Transplant & Cellular Therapies Research, University of California, San Francisco, Benioff Children's Hospital of Oakland 2:20–2:30 Benz, Jr., M.D., Executive Director, National Edward Institutes of Health Cure Sickle Cell Initiative 2:30–2:40 Celia Witten, Ph.D., M.D., Deputy Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration 2:40–3:00 Discussion 3:00 Public Comments Read the entire page →
From page 423... ... Riehm Meier, M.D., M.S.H.S., Pediatric Emily Hematologist and Director, Sickle Cell Research, Indiana Hemophilia and Thrombosis Center, Inc. Donna McCurry, A.P.R.N., F.N.P.-B.C., Senior Nurse Practitioner and Program Manager, Comprehensive Sickle Cell Resource Center, Truman Medical Centers, Kansas City, Missouri 2:25 Break Read the entire page →
From page 424... ... Whisenton Jennifer Nsenkyire Teonna Woolford Jackson Jacques (Jackie) 5:10 Public Comments 5:30 Closing Remarks Marie Clare McCormick, M.D., Sc.D., Committee Chair 5:45 OPEN SESSION ENDS Read the entire page →
From page 425... ... emophilia of Georgia Center for Bleeding and H Clotting Disorders of Emory Christine L Kempton, M.D., M.Sc., Director 10:15–10:45 SCD as a Public Health Issue and CDC Efforts Mary Hulihan, Dr.P.H., Health Scientist, Epidemiology and Surveillance Branch, Division of Blood Disorders, Centers for Disease Control and Prevention 10:45–11:00 Break 11:00 a.m.– Patient Panel 12:30 p.m. Read the entire page →
From page 426... ... Elliott, M.D., Clinical Development Brian Medical Director, Novartis Ho, M.D., Executive Vice President of Tony Research & Development, CRISPR Therapeutics Love, M.D., President and Chief Executive Ted Officer, Global Blood Therapeutics 9:50–10:20 a.m. Closing Remarks and Discussion Read the entire page →

From page 419...

... Department of Health and Human Services 2:30–2:50 Epidemiology of Sickle Cell Disease in the United States Mary Hulihan, Dr.P.H., Health Scientist, Epidemiology and Surveillance Branch, Division of Blood Disorders, Centers for Disease Control and Prevention 419

Read the entire page →

From page 420...

... Taylor VI, D isease, Howard University 3:30–4:00 of Advocacy in Improving the Patient Experience The Role and Outcomes Shirley Miller, M.A., Patient Advocate, Atrium Health Lakiea Bailey, Ph.D., Executive Director, Sickle Cell Community Consortium 4:00–4:30 Public Comments SECOND PUBLIC MEETING April 16, 2019 Keck Center of the National Academies 500 Fifth Street, NW Washington, DC 20001 Open Session 9:30 a.m. Welcome and Opening Remarks Marie Clare McCormick, M.D., Sc.D., Committee Chair 9:45 Impact of Sickle Cell Disease on Patients, Panel 1: The Families, and Communities Facilitator: Charmaine Royal, Ph.D., M.S., Committee Member 9:45–9:50 Panel Introductions 9:50–10:00 Robertson, M.B.A., J.D., Patient Advocate; Derek Co-Founder, Maryland Sickle Cell Disease Association 10:00–10:10 Adrienne Bell-Cors Shapiro, Co-Founder and Science Administrator, Axis Advocacy

Read the entire page →

From page 421...

... Department of Education 11:25–11:35 P Weishaupt, J.D., Senior Attorney, Health Richard and Human Services, Community Legal Services of Philadelphia 11:35–11:45 Whitten-Shurney, M.D., Chief Executive Wanda Officer and Medical Director, Sickle Cell Disease Association of America, Michigan Chapter, Inc.

Read the entire page →

From page 422...

... 422 ADDRESSING SICKLE CELL DISEASE 12:50–1:00 Speller-Brown, D.N.P., P.N.P.-B.C., Director, Barbara SCD Transition Clinic; Lead Sickle Cell Translational Research APN, Children's National Health System 1:00–1:10 Jeffrey Glassberg, M.D., Associate Professor, Emergency Medicine; Hematology and Medical Oncology, Mount Sinai 1:10–1:20 Jonassaint, Ph.D., Assistant Professor of Charles Medicine, Social Work and Clinical and Translational Science, Department of Medicine, University of Pittsburgh 1:20–1:40 Discussion 1:40 Break 1:55 Panel 4: Curative Therapies for Sickle Cell Disease Lakdawalla, Ph.D., Committee Facilitator: Darius Member 1:55–2:00 Panel Introductions 2:00–2:10 Betsy Myers, Ph.D., Program Director for Medical Research, Doris Duke Charitable Foundation 2:10–2:20 Mark Walters, M.D., Program Director, Alpha Stem Cell Clinic; Medical Director, Jordan Family Center for Bone Marrow Transplant & Cellular Therapies Research, University of California, San Francisco, Benioff Children's Hospital of Oakland 2:20–2:30 Benz, Jr., M.D., Executive Director, National Edward Institutes of Health Cure Sickle Cell Initiative 2:30–2:40 Celia Witten, Ph.D., M.D., Deputy Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration 2:40–3:00 Discussion 3:00 Public Comments

Read the entire page →

From page 423...

... Riehm Meier, M.D., M.S.H.S., Pediatric Emily Hematologist and Director, Sickle Cell Research, Indiana Hemophilia and Thrombosis Center, Inc. Donna McCurry, A.P.R.N., F.N.P.-B.C., Senior Nurse Practitioner and Program Manager, Comprehensive Sickle Cell Resource Center, Truman Medical Centers, Kansas City, Missouri 2:25 Break

Read the entire page →

From page 424...

... Whisenton Jennifer Nsenkyire Teonna Woolford Jackson Jacques (Jackie) 5:10 Public Comments 5:30 Closing Remarks Marie Clare McCormick, M.D., Sc.D., Committee Chair 5:45 OPEN SESSION ENDS

Read the entire page →

From page 425...

... emophilia of Georgia Center for Bleeding and H Clotting Disorders of Emory Christine L Kempton, M.D., M.Sc., Director 10:15–10:45 SCD as a Public Health Issue and CDC Efforts Mary Hulihan, Dr.P.H., Health Scientist, Epidemiology and Surveillance Branch, Division of Blood Disorders, Centers for Disease Control and Prevention 10:45–11:00 Break 11:00 a.m.– Patient Panel 12:30 p.m.

Read the entire page →

From page 426...

... Elliott, M.D., Clinical Development Brian Medical Director, Novartis Ho, M.D., Executive Vice President of Tony Research & Development, CRISPR Therapeutics Love, M.D., President and Chief Executive Ted Officer, Global Blood Therapeutics 9:50–10:20 a.m. Closing Remarks and Discussion

Read the entire page →

← Previous Chapter Skim

Next Chapter Skim →

This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.

Appendix A: Public Meeting Agendas and Submissions to the Committee Pages 419-426

Appendix A: Public Meeting Agendas and Submissions to the Committee
Pages 419-426